<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Immune effector cell-associated neurotoxicity syndrome (ICANS)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Immune effector cell-associated neurotoxicity syndrome (ICANS)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Immune effector cell-associated neurotoxicity syndrome (ICANS)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jorg Dietrich, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Matthew J Frigault, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patrick Y Wen, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 14, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H4100349471">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immune effector cell-associated neurotoxicity syndrome (ICANS)
         <em>
         </em>
         is a clinical and neuropsychiatric syndrome that can occur in the days to weeks following administration of certain types of immunotherapy, especially immune effector cell (IEC) and T cell engaging therapies. It has previously been referred to as cytokine release encephalopathy syndrome (CRES) and chimeric antigen receptor T (CAR-T) cell-related encephalopathy or neurotoxicity.
        </p>
        <p>
         ICANS is seen at varying degrees of severity and has been associated with fatal outcomes in rare cases. Given the rapidly expanding use of IEC therapies, it is imperative for all clinicians involved in the care of treated patients to be familiar with the manifestations and management of ICANS.
        </p>
        <p>
         CAR-T cell therapies are available for treatment of relapsed and refractory hematologic malignancies and are also under investigation in a range of solid tumors. CD19-targeting CAR-T cell products approved by the US Food and Drug Administration (FDA) include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="114674" href="/z/d/drug information/114674.html" rel="external">
          Tisagenlecleucel
         </a>
         <em>
         </em>
         for relapsed/refractory B cell acute lymphoblastic leukemia and relapsed/refractory large B cell lymphoma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="115350" href="/z/d/drug information/115350.html" rel="external">
          Axicabtagene ciloleucel
         </a>
         for relapsed/refractory large B cell lymphoma and relapsed/refractory follicular lymphoma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="129101" href="/z/d/drug information/129101.html" rel="external">
          Brexucabtagene autoleucel
         </a>
         <em>
         </em>
         for relapsed/refractory mantle cell lymphoma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="130728" href="/z/d/drug information/130728.html" rel="external">
          Lisocabtagene maraleucel
         </a>
         for relapsed/refractory large B cell lymphoma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="131213" href="/z/d/drug information/131213.html" rel="external">
          Idecabtagene vicleucel
         </a>
         for relapsed/refractory multiple myeloma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="135088" href="/z/d/drug information/135088.html" rel="external">
          Ciltacabtagene autoleucel
         </a>
         for relapsed/refractory multiple myeloma
        </p>
        <p>
        </p>
        <p>
         This topic will discuss the epidemiology, pathophysiology, clinical features, evaluation, and management of ICANS. Cytokine release syndrome (CRS) is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/118012.html" rel="external">
          "Cytokine release syndrome (CRS)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H616488787">
         <span class="h1">
          INCIDENCE AND RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of ICANS varies depending on the type of therapy being delivered, disease and patient characteristics, and because the definition and recognition of the syndrome has changed over time [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1122580156">
         <span class="h2">
          Specific products
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapies most commonly associated with ICANS are chimeric antigen receptor T (CAR-T) cell therapies and certain T cell engaging therapies such as
         <a class="drug drug_general" data-topicid="98582" href="/z/d/drug information/98582.html" rel="external">
          blinatumomab
         </a>
         and
         <a class="drug drug_general" data-topicid="139997" href="/z/d/drug information/139997.html" rel="external">
          teclistamab
         </a>
         .
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CAR-T cell therapies
         </strong>
         – ICANS of any severity occurs in 20 to 70 percent of patients treated with CAR-T cell therapy [
         <a href="#rid3">
          3-9
         </a>
         ]. Severe ICANS has been observed in the pivotal studies of all six products  (
         <a class="graphic graphic_table graphicRef130108" href="/z/d/graphic/130108.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid5">
          5,8-10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Differences in the costimulatory domains of each product affect neurotoxicity risk [
         <a href="#rid11">
          11-13
         </a>
         ]. Among the available products, rates and severity of ICANS are generally higher with
         <a class="drug drug_general" data-topicid="115350" href="/z/d/drug information/115350.html" rel="external">
          axicabtagene ciloleucel
         </a>
         and
         <a class="drug drug_general" data-topicid="129101" href="/z/d/drug information/129101.html" rel="external">
          brexucabtagene autoleucel
         </a>
         , which have CD28-containing CAR-T constructs and are associated with more rapid T cell expansion kinetics, effector memory T cell differentiation, and glycolic metabolism [
         <a href="#rid14">
          14,15
         </a>
         ], compared with
         <a class="drug drug_general" data-topicid="114674" href="/z/d/drug information/114674.html" rel="external">
          tisagenlecleucel
         </a>
         ,
         <a class="drug drug_general" data-topicid="130728" href="/z/d/drug information/130728.html" rel="external">
          lisocabtagene maraleucel
         </a>
         ,
         <a class="drug drug_general" data-topicid="131213" href="/z/d/drug information/131213.html" rel="external">
          idecabtagene vicleucel
         </a>
         , and
         <a class="drug drug_general" data-topicid="135088" href="/z/d/drug information/135088.html" rel="external">
          ciltacabtagene autoleucel
         </a>
         , which have a 4-1BB-containing CAR construct that supports more oxidative metabolism with slower T cell expansion kinetics, a central memory T cell phenotype, and potentially longer-term persistence [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Structural differences and manufacturing variability also affect risk, making comparisons of incidence based purely on transgene structure limited. Across different products, higher CAR-T cell doses and peak CAR-T cell expansion are associated with increased ICANS incidence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Comparisons of toxicity across early trials is difficult due to differences in grading systems (Common Terminology Criteria for Adverse Events [CTCAE] version 4.03 versus Penn Criteria) as well as use of different management algorithms, with earlier studies intervening at higher grades due to concerns of impacting treatment efficacy. With improved management strategies, there has been a relative reduction in toxicities; however, key product differences remain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          T cell engaging therapies
         </strong>
         – The frequency and pattern of ICANS associated with T cell engaging therapies is less well characterized than with early-generation CD19-targeted CAR-T cell therapies, and data are evolving.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Neurologic toxicity occurs in approximately 65 percent of patients treated with
         <a class="drug drug_general" data-topicid="98582" href="/z/d/drug information/98582.html" rel="external">
          blinatumomab
         </a>
         , a CD19/CD3 bispecific T cell engager for treatment of B cell acute lymphoblastic leukemia [
         <a href="#rid17">
          17,18
         </a>
         ]. The most common manifestations are headache and tremor. CTCAE grade 3 or higher toxicities (severe, life-threatening, or fatal) have been seen in approximately 13 percent of patients, including encephalopathy, seizures, disturbances of speech and consciousness, confusion, disorientation, and imbalance. Blinatumomab-associated neurotoxicity is the most common reason for dose interruption; however, neurologic symptoms usually resolve with drug hold and typically decrease with subsequent cycles [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The risk of ICANS of any severity is also elevated (&gt;50 percent) with
         <a class="drug drug_general" data-topicid="139997" href="/z/d/drug information/139997.html" rel="external">
          teclistamab
         </a>
         , a B cell maturation antigen (BCMA)/CD3 bispecific T cell engager for treatment of multiple myeloma [
         <a href="#rid20">
          20
         </a>
         ]. By contrast, the risk of ICANS appears to be much lower (&lt;10 percent) with
         <a class="drug drug_general" data-topicid="142431" href="/z/d/drug information/142431.html" rel="external">
          elranatamab
         </a>
         , also a BCMA/CD3 T cell engager for multiple myeloma [
         <a href="#rid21">
          21
         </a>
         ];
         <a class="drug drug_general" data-topicid="140391" href="/z/d/drug information/140391.html" rel="external">
          mosunetuzumab
         </a>
         , a CD20/CD3 T cell engager for follicular lymphoma [
         <a href="#rid22">
          22
         </a>
         ];
         <a class="drug drug_general" data-topicid="141793" href="/z/d/drug information/141793.html" rel="external">
          glofitamab
         </a>
         , a CD20/CD3 binder for diffuse large B-cell lymphoma (DLBCL) [
         <a href="#rid23">
          23
         </a>
         ];
         <a class="drug drug_general" data-topicid="141559" href="/z/d/drug information/141559.html" rel="external">
          epcoritamab
         </a>
         , a CD20/CD3 binder for DLBCL [
         <a href="#rid24">
          24
         </a>
         ]; and
         <a class="drug drug_general" data-topicid="142419" href="/z/d/drug information/142419.html" rel="external">
          talquetamab
         </a>
         , a GPRC5D/CD3 T cell engager for multiple myeloma [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4118617288">
         <span class="h2">
          Clinical risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Across different products and studies, clinical risk factors associated with increased risk of ICANS include [
         <a href="#rid2">
          2,7,26-30
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Younger patient age
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preexisting neurologic and medical comorbidities
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High disease burden of the underlying malignancy
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased intensity of lymphodepleting therapy and cytopenias
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Early and severe cytokine release syndrome (CRS) with high levels of inflammatory cytokines
        </p>
        <p>
        </p>
        <p>
         Of note, the pivotal studies of all approved CAR-T cell therapies excluded patients with active central nervous system (CNS) disease given concern for increased risk of ICANS. However, subsequent work has demonstrated that CAR-T can be used safely in patients with CNS malignancies with appropriate management, as ICANS is likely a neurologic manifestation of an otherwise systemic process [
         <a href="#rid31">
          31,32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3626478896">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathophysiology of ICANS and the mechanisms underlying many of the symptoms are not fully understood.
        </p>
        <p>
         In general, it is thought that systemic inflammation and high levels of circulating cytokines result in endothelial cell activation and blood-brain barrier (BBB) disruption, which in turn causes an inflammatory cascade within the central nervous system (CNS), subsequent alterations in cortical and subcortical function, and diffuse cerebral edema in some cases.
        </p>
        <p>
         Both ICANS and cytokine release syndrome (CRS) are considered an enhanced or supraphysiologic immune response to immune-modulating therapy that activates or engages T cells and/or other immune effector cells (IECs). CAR-T-related ICANS is commonly associated with, and follows, CRS, suggesting a potential mechanistic link. Clinical correlates of severe ICANS often overlap with severe CRS, including elevations in C-reactive protein (CRP), ferritin, and cytopenias [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/118012.html" rel="external">
          "Cytokine release syndrome (CRS)", section on 'Pathophysiology'
         </a>
         .)
        </p>
        <p>
         While there was early speculation that neurotoxicity was antigen specific, since ICANS was observed both with the CD19-specific T cell engager,
         <a class="drug drug_general" data-topicid="98582" href="/z/d/drug information/98582.html" rel="external">
          blinatumomab
         </a>
         , and with CD19-specific chimeric antigen receptor T (CAR-T) therapies, subsequent reports have clearly identified ICANS in other, non-CD19-associated applications and diseases [
         <a href="#rid34">
          34,35
         </a>
         ]. Based on one clinical trial experience, it is possible that some delayed toxicities may be antigen specific, however. (See
         <a class="local">
          'Delayed parkinsonism'
         </a>
         below.)
        </p>
        <p>
         Endothelial activation and disruption of the BBB have been identified as potential mechanisms [
         <a href="#rid26">
          26,36,37
         </a>
         ]. The angiopoietin (ANG) and angiopoietin receptor (TIE) axis is disrupted during an initial inflammatory insult, likely mediated, in part, by tumor necrosis factor alpha (TNF-alpha), interleukin (IL) 6, and IL-1. This results in endothelial activation and microvascular permeability, including BBB breakdown. With increased BBB permeability, patients with severe ICANS also exhibit elevated CNS levels of cytokines, protein, and T cell infiltrates [
         <a href="#rid38">
          38-41
         </a>
         ].
        </p>
        <p>
         In addition to CAR-T activation, recruitment and activation of other immune competent cells have been implicated, including myeloid cells, monocytes, and macrophages. Studies in patients with CAR-T cell-associated neurotoxicity have shown elevations in inflammatory cytokines (eg, interferon gamma [IFN-gamma], IL-6, IL-8, IL-10, granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor [GM-CSF], monocyte chemoattractant protein 1 [MCP-1], interferon gamma-induced protein 10 [IP-10]), markers of astrocyte injury (eg, glial fibrillary acidic protein [GFAP], S100 calcium-binding protein B [S100B]), and neurotoxic substances (eg, glutamate and quinolinic acid) [
         <a href="#rid26">
          26,27,42-44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3880417825">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H1785842315">
         <span class="h2">
          Clinical presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical presentation of ICANS ranges from mild alterations in the level of consciousness to varying degrees of neurologic dysfunction, including [
         <a href="#rid1">
          1,7,26,27,45
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Encephalopathy with confusion and behavioral changes
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Visual and auditory hallucinations
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Language dysfunction, speech alterations, and apraxia
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Headache, fatigue, and tremors
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dysgraphia and other fine motor impairment
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical or subclinical seizures, including status epilepticus
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cerebral edema with coma
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Death secondary to malignant cerebral edema
        </p>
        <p>
        </p>
        <p>
         ICANS most often develops within 3 to 10 days after chimeric antigen receptor T (CAR-T) cell administration, but the timing can vary among CAR-T cell products and disease indications [
         <a href="#rid7">
          7,26,27,46
         </a>
         ]. ICANS usually occurs in the context of cytokine release syndrome (CRS), with neurologic symptoms beginning within two to four days of the onset of CRS. However, CRS is not required for ICANS, and the syndromes can occur at different times. (See
         <a class="medical medical_review" href="/z/d/html/118012.html" rel="external">
          "Cytokine release syndrome (CRS)", section on 'Clinical presentation'
         </a>
         .)
        </p>
        <p>
         Initial neurologic symptoms are usually characterized by inattention and language deficits [
         <a href="#rid7">
          7,28,47,48
         </a>
         ]. Clinical symptoms can be rapidly progressive within hours to a few days. Close monitoring during this time is critical.
        </p>
        <p>
         Mildly affected patients may be disoriented but able to communicate, with mild expressive and/or receptive language dysfunction  (
         <a class="graphic graphic_table graphicRef122197" href="/z/d/graphic/122197.html" rel="external">
          table 2
         </a>
         ). Worsening signs of encephalopathy include decreased level of consciousness, slowness to respond, and disorientation to time and location. Severely affected patients can have language dysfunction or mutism, experience seizures, and be difficult to arouse (ie, only responsive to tactile or noxious stimulation). (See
         <a class="local">
          'Grading'
         </a>
         below.)
        </p>
        <p>
         The frequency of clinical seizures in patients with ICANS is difficult to estimate, in part because some patients have involuntary movements and intermittent neurologic symptoms that do not correlate with an ictal pattern on electroencephalography (EEG). In addition, seizure risk may be influenced by use of prophylactic antiseizure medications, which was not standard in early trials but has become more widely adopted. Based on early studies, the risk of seizure was estimated to be as high as 50 percent in patients with ICANS and 30 percent of all patients treated with CAR-T cell therapy [
         <a href="#rid27">
          27
         </a>
         ]. Later studies report a seizure incidence between 1 and 30 percent in patients with ICANS and 0 to 10 percent of patients treated with CAR-T cells in general [
         <a href="#rid7">
          7,28,49
         </a>
         ].
        </p>
        <p>
         The acute symptoms of ICANS are considered reversible and usually resolve within 7 to 10 days of onset with adequate management. Nevertheless, neurotoxicity can be life threatening and/or extended, with some patients requiring prolonged intensive care unit (ICU) monitoring and mechanical ventilation for airway protection and management of elevated intracranial pressure (ICP). In fatal cases, the cause of death has primarily been attributed to malignant cerebral edema [
         <a href="#rid45">
          45,50
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1710837957">
         <span class="h2">
          Laboratories
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratories in patients with ICANS often, but not always, show evidence of systemic inflammation due to concomitant CRS.
        </p>
        <p>
         Blood biomarkers that have been associated with higher risk for developing neurotoxicity include high lactate dehydrogenase (LDH) levels (as a marker of disease burden), significant thrombocytopenia (as a marker of bone marrow toxicity in heavily pretreated patients), and rising inflammatory markers such as ferritin, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR; as evidence of cytokine release and immune activation) [
         <a href="#rid7">
          7,30
         </a>
         ].
        </p>
        <p>
         Patients with severe ICANS exhibit high serum levels of proinflammatory cytokines such as interleukin (IL) 2, IL-6, IL-15, interferon gamma (IFN-gamma), and tumor necrosis factor alpha (TNF-alpha). While such biomarkers have so far not been routinely used in clinical practice, CRP and ferritin levels are easily obtained, and rising CRP/ferritin is a clinically helpful biomarker associated with an elevated risk for ICANS [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Cerebrospinal fluid (CSF) findings in patients with ICANS are nonspecific. CSF may be normal or may show mild protein elevation and pleocytosis [
         <a href="#rid28">
          28,30
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1104921723">
         <span class="h2">
          Electroencephalography
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with ICANS have an abnormal EEG, reflective of some degree of encephalopathy and, less commonly, electrographic seizures.
        </p>
        <p>
         Frontal or diffuse theta-delta background slowing is the most commonly observed pattern [
         <a href="#rid51">
          51,52
         </a>
         ]. Other findings include generalized periodic discharges (GPDs), generalized rhythmic delta activity (GRDA), bilateral periodic discharges (BiPEDs), and frank electrographic seizures and status epilepticus [
         <a href="#rid49">
          49,52,53
         </a>
         ].
        </p>
        <p>
         It is not yet clear whether the degree of ICANS correlates with specific EEG findings. In an analysis of the continuous EEGs of 81 patients with neurotoxicity after CAR-T cell therapy, the degree of background slowing and loss of posterior-dominant rhythm correlated with neurotoxicity severity but not with duration [
         <a href="#rid52">
          52
         </a>
         ]. Rhythmic or periodic patterns such as GRDA were common but did not invariably correlate with higher neurotoxicity grade. Among five patients with clinical seizures (6 percent), all but one had focally abnormal EEGs within the ictal-interictal continuum and/or with rhythmic/periodic patterns.
        </p>
        <p class="headingAnchor" id="H1865474542">
         <span class="h2">
          Neuroimaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with ICANS have normal neuroimaging studies, even in the context of clinically established CRS and ICANS [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         In severe ICANS complicated by increased ICP, computed tomography (CT) and magnetic resonance imaging (MRI) of the brain may show diffuse white matter changes and sulcal effacement, indicative of diffuse cerebral edema  (
         <a class="graphic graphic_diagnosticimage graphicRef130036" href="/z/d/graphic/130036.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid50">
          50,54
         </a>
         ]. Other abnormal findings that have been described infrequently in patients with ICANS include cerebral infarctions, subarachnoid or subdural hemorrhage, and focal or diffuse white matter injury [
         <a href="#rid7">
          7,27,28
         </a>
         ].
        </p>
        <p>
         Focal vascular abnormalities on CT angiography have been described in a minority of patients, including at least one case of vasospasm suggested by partial resolution on two-week follow-up imaging [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3710581663">
         <span class="h1">
          GRADING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Grading of ICANS  (
         <a class="graphic graphic_table graphicRef122197" href="/z/d/graphic/122197.html" rel="external">
          table 2
         </a>
         ) has evolved since early clinical trials of chimeric antigen receptor T (CAR-T) therapy. Guidelines from the American Society for Transplantation and Cellular Therapy (ASTCT) attempt to harmonize earlier scales, including the CAR-T Cell Therapy-Associated Toxicity (CARTOX-10) criteria, and recognize the growing diversity in immune effector cell (IEC) therapies and the potential for neurotoxicity outside of CAR-T applications [
         <a href="#rid1">
          1,47,55
         </a>
         ].
        </p>
        <p>
         The ASTCT grading scale includes a 10-point encephalopathy assessment, termed the "immune effector cell-associated encephalopathy" (ICE) score, which builds on the previous CARTOX-10 element for assessing receptive aphasia. The ICE score has five components: orientation, naming, following commands, writing, and attention.
        </p>
        <p>
         Patients are graded according to the most severe symptom attributable to ICANS in five domains: encephalopathy (ICE score), level of consciousness, seizure, motor findings, and elevated intracranial pressure (ICP)/cerebral edema  (
         <a class="graphic graphic_table graphicRef122197" href="/z/d/graphic/122197.html" rel="external">
          table 2
         </a>
         ). As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Grade 1 (mild)
         </strong>
         – A patient with grade 1 ICANS may demonstrate inattentiveness, mild disorientation, and mild expressive and/or receptive language dysfunction but will be able to communicate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Grade 2 (moderate)
         </strong>
         – A patient with grade 2 ICANS may have a moderately impaired level of consciousness but is responsive to voice, usually slow to respond, and disoriented to time and location.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Grade 3/4 (severe)
         </strong>
         – Grade 3/4 ICANS includes patients with more severe and significant language dysfunction or mutism, those who are difficult to arouse (ie, only responsive to tactile or noxious stimulation), and potentially those with seizures.
        </p>
        <p>
        </p>
        <p>
         Although the ICE assessment is useful for screening adults for encephalopathy, it is not optimized for children. For children age &lt;12 years, or those with developmental delay, the Cornell Assessment of Pediatric Delirium (CAPD) is recommended to aid in the overall grading of ICANS [
         <a href="#rid56">
          56
         </a>
         ]. Other domains are the same as in adults: level of consciousness, motor symptoms, seizures, and signs of raised ICP.
        </p>
        <p>
         Of note, neurotoxicity associated with non-IEC therapies (eg, bispecific antibodies) is graded using the standard Common Terminology Criteria for Adverse Events (CTCAE) version 5.0  (
         <a class="graphic graphic_table graphicRef78736" href="/z/d/graphic/78736.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef91811" href="/z/d/graphic/91811.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid55">
          55
         </a>
         ], as the ICANS/ICE system only pertains to IEC therapies [
         <a href="#rid1">
          1
         </a>
         ]. IECs can be any cell used to modulate an immune response for therapeutic intent, such as dendritic cells, natural killer cells, T cells, and B cells. This includes genetically engineered CAR-T cells and therapeutic vaccines [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H641233854">
         <span class="h1">
          EVALUATION AND DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         ICANS is a clinical diagnosis of neurologic toxicity attributed to recent administration of an immune effector cell (IEC) therapy or T cell engaging therapy. It is a diagnosis of exclusion after other potential causes of mental status changes or altered neurologic function have been ruled out.
        </p>
        <p class="headingAnchor" id="H3656087353">
         <span class="h2">
          Clinical monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who receive chimeric antigen receptor T (CAR-T) cell therapy,
         <a class="drug drug_general" data-topicid="98582" href="/z/d/drug information/98582.html" rel="external">
          blinatumomab
         </a>
         , and
         <a class="drug drug_general" data-topicid="139997" href="/z/d/drug information/139997.html" rel="external">
          teclistamab
         </a>
         require close monitoring for the development of cytokine release syndrome (CRS) and ICANS.
        </p>
        <p>
         Decisions to treat patients as inpatients or outpatients should be based on product-specific toxicity profiles, the time course of toxicity, and center-specific infrastructure for safety and monitoring.
        </p>
        <p>
         In the United States, the US Food and Drug Administration (FDA) has mandated risk evaluation and mitigation strategies (REMS), and all centers providing commercial CAR-T cell products must be authorized prior to treating patients. Some FDA-approved products (such as
         <a class="drug drug_general" data-topicid="115350" href="/z/d/drug information/115350.html" rel="external">
          axicabtagene ciloleucel
         </a>
         ) require daily clinical evaluations for the first week following CAR-T infusion.
        </p>
        <p>
         A baseline neurologic examination should be performed prior to administration of CAR-T cells in order to establish a patient-specific neurologic baseline.
        </p>
        <p>
         Standard daily clinical assessment for ICANS includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical examination and review of vital signs
         </strong>
         – More frequent clinical evaluations and bedside assessments are recommended in patients at higher risk for neurotoxicity, such as in patients with fever and other signs of CRS, preexisting neurologic deficits, and any evidence of change in mental status.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Routine neurologic examination
         </strong>
         – There should be particular focus on subtle deficits in attention and changes in alertness and language function, as these are usually the earliest signs of ICANS. Family members and the nursing team may have insight into subtle personality changes or other deviations from baseline not readily detected by routine examination. Assessment should be repeated at least twice a day and with any change in status.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bedside funduscopy
         </strong>
         – Funduscopy is particularly important in patients with altered mental status and visual changes, to assess for signs of increased intracranial pressure (ICP) and possible cerebral edema.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immune effector cell-associated encephalopathy (ICE) score
         </strong>
         – The ICE score  (
         <a class="graphic graphic_table graphicRef122197" href="/z/d/graphic/122197.html" rel="external">
          table 2
         </a>
         ) should be performed as part of any routine assessment during the at-risk period (typically the 30-day period following CAR-T infusion). This helps to standardize, quantify, and trend a patient's neurologic status. (See
         <a class="local">
          'Grading'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory review
         </strong>
         – Serial monitoring of laboratory tests helps to inform the index of suspicion for CRS and ICANS. ICANS usually presents in a temporal relationship to CRS, and most patients develop neurologic deficits within days after CRS onset. Daily laboratory tests should include complete blood counts, chemistry profile, prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, and routine inflammatory markers, such as ferritin and C-reactive protein (CRP).
        </p>
        <p>
        </p>
        <p>
         Changes in the neurologic examination should be interpreted in the context of a broad differential diagnosis. Patients receiving CAR-T cell therapy are usually heavily pretreated with chemotherapy and at risk for multiple causes of altered mental status, including medication side effects, infection, new or worsening renal or liver dysfunction, and changes in electrolytes and endocrine function. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1362321170">
         <span class="h2">
          Additional testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional testing of patients with suspected ICANS may include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          EEG
         </strong>
         – EEG is an important tool in the evaluation of suspected ICANS. Any patient with unexplained altered mental status, including ICANS, should undergo EEG recording to diagnose or rule out subclinical or nonconvulsive seizures that otherwise would not be readily detectable by a clinical bedside examination.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While ICANS does not have a specific EEG signature, EEG is often uniquely helpful to support the diagnosis and degree of encephalopathy and offer clues regarding the potential differential diagnosis (eg, seizures versus metabolic causes). Additionally, as seizure activity is required for ICANS grading, patients should be evaluated for seizure activity as part of routine ICANS assessment. Long-term EEG monitoring can be helpful in patients with prolonged or fluctuating encephalopathy and mental status changes to guide management and adjustment of antiseizure medications [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neuroimaging
         </strong>
         –
         <strong>
         </strong>
         A noncontrast head CT is indicated in
         <strong>
         </strong>
         patients with rapidly
         <strong>
         </strong>
         worsening mental status or acute focal deficits to rule out cerebral edema or other acute abnormalities (eg, bleeding) and to guide further management, such as escalating care and need for intensive care unit (ICU) monitoring.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When possible, brain MRI is strongly recommended in patients with worsening ICANS as part of the workup for other etiologies of neurologic dysfunction and to evaluate for cerebral edema and more subtle changes in cerebral white matter. This may be difficult in patients with agitated delirium; MRI can be deferred in such cases pending patient stability.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lumbar puncture
         </strong>
         – We perform lumbar puncture (LP) selectively in patients with ICANS. The cerebrospinal fluid (CSF) findings in ICANS are nonspecific and do not rule in or out the diagnosis. The main indication for LP is when there is clinical suspicion for central nervous system (CNS) infection or neoplastic CNS involvement. Neuroimaging, as well as platelet count and coagulation studies, should be reviewed before LP to ensure safety.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Particular caution is required before performing an LP in a patient with severe (grade 3 or 4) ICANS, as an LP can trigger herniation in the setting of diffuse cerebral edema. In addition, many of these patients have a coagulopathy and increased risk for bleeding complications; therefore, clinical risk/benefit should be assessed. If there is significant clinical concern for meningitis or other CNS infection and a contraindication to LP, appropriate antimicrobial therapy should be started empirically.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3497284581">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of ICANS is broad, and evaluation can be challenging. Patients treated with CAR-T cells are often quite ill and deconditioned, are often heavily pretreated, and commonly present with more than one clinical symptom (eg, mental status changes in combination with fever, low blood counts, and/or electrolyte abnormalities).
        </p>
        <p>
         The list of alternative diagnoses varies depending on the lead clinical symptom(s) (eg, encephalopathy versus new focal neurologic deficit), the temporal course (eg, acute, subacute, fluctuating, progressive), and the duration of the abnormality.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Encephalopathy
         </strong>
         – In any patient with the acute or subacute onset of encephalopathy, initial considerations include adverse effects from medications (eg, opioids, other sedating medications), metabolic abnormalities (eg, renal or liver impairment), endocrine dysfunction (eg, adrenal insufficiency, thyroid dysfunction), infections (including systemic or CNS infections), seizures (clinical or subclinical), and even psychiatric etiologies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Medication review and appropriate laboratories will identify most of these culprits. EEG can also be helpful and is often necessary to rule out subclinical seizures. (See
         <a class="local">
          'Additional testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Focal or rapidly progressive deficits
         </strong>
         – Additional considerations in patients with focal or rapidly worsening deficits include seizure, intracranial hemorrhage, stroke, and intracranial infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A noncontrast head CT will serve to identify acute bleeding or evidence of life-threatening cerebral edema. A brain MRI with and without contrast will have better sensitivity for acute ischemia, white matter injury, leptomeningeal processes, and other alternative CNS etiologies. CSF testing is indicated if there is clinical suspicion for meningitis or encephalitis.
        </p>
        <p>
        </p>
        <p>
         Many other neurologic disorders may present in the days to weeks following CAR-T cell therapy with shared features of ICANS. Repeated examinations and multidisciplinary input are often required to establish the correct diagnosis. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tumor progression within the CNS
         </strong>
         – Tumor progression within the CNS can occur at any time in relation to receipt of anticancer therapies. The index of suspicion is typically highest in patients being treated for CNS malignancies or with systemic lymphoma/leukemias with a high rate of spread to the nervous system. When neuroimaging and/or CSF are equivocal, repeated examinations and occasionally biopsy may be necessary.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fludarabine-associated neurotoxicity
         </strong>
         – Delayed neurologic complications from prior conventional cytotoxic chemotherapy can be a confounding factor. Specifically, fludarabine-associated neurotoxicity may present with delayed
         <em>
         </em>
         and slowly progressive cognitive decline, visual disturbances, peripheral neuropathy, weakness, ataxia, and even death from 20 to 250 days following drug exposure [
         <a href="#rid59">
          59,60
         </a>
         ]. MRI may demonstrate areas of restricted diffusion and leukoencephalopathy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          Fludarabine
         </a>
         is increasingly used as part of the lymphodepleting regimen prior to CAR-T cell administration, and clinicians should be cautious of fludarabine dosing and fluctuations in creatine clearance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reversible posterior leukoencephalopathy syndrome (RPLS)
         </strong>
         – RPLS can be caused by numerous drugs and chemotherapy agents and can be seen in the context of elevated blood pressure [
         <a href="#rid51">
          51,61,62
         </a>
         ]. Clinical symptoms may include headache, mental status changes, visual disturbances, and seizures. Brain MRI classically shows cortical or subcortical, posterior-predominant T2/fluid-attenuated inversion recovery (FLAIR) hyperintensities and diffusion restriction, although central patterns are also seen. (See
         <a class="medical medical_review" href="/z/d/html/4835.html" rel="external">
          "Reversible posterior leukoencephalopathy syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Progressive multifocal leukoencephalopathy (PML)
         </strong>
         – PML is caused by reactivation of the JC polyomavirus and can be seen after chemotherapy or immunomodulatory therapy, or in other conditions associated with an immunocompromised state [
         <a href="#rid63">
          63-65
         </a>
         ]. PML manifests as abnormal T2/FLAIR hyperintensity on brain MRI, usually beginning in the subcortical white matter of the parietal or occipital lobes. Cortex, cerebellum, and deep gray structures can also be involved. CSF JC virus testing can be diagnostic. (See
         <a class="medical medical_review" href="/z/d/html/1694.html" rel="external">
          "Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3422659646">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of patients with ICANS requires vigilance and close supportive care, and early recognition is paramount. Treatment is supportive and consists primarily of glucocorticoids and antiseizure therapy. While neurologic deficits are considered transient and are usually reversible with appropriate management, fatal outcomes have been reported secondary to malignant cerebral edema.
        </p>
        <p>
         Treatment recommendations are based primarily on clinical experience and observational data. Consensus guidelines for patient evaluation and management are available from the Society for Immunotherapy of Cancer (SITC) and the American Society of Clinical Oncology (ASCO) [
         <a href="#rid66">
          66,67
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H883908437">
         <span class="h2">
          General considerations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of patients with ICANS can be challenging, and neurologic symptoms may develop rapidly. Most patients have progressive cancer despite multiple prior therapies and as a result are often deconditioned and frail, medically complicated, and immunosuppressed.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Daily monitoring
         </strong>
         – A baseline neurologic examination should be performed prior to administration of chimeric antigen receptor T (CAR-T) cell therapy and daily for at least the first week after treatment. Components of the daily assessment are reviewed above. (See
         <a class="local">
          'Clinical monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severity assessment
         </strong>
         – Management decisions are informed by ICANS severity. The American Society for Transplantation and Cellular Therapy (ASTCT) grading scale is the preferred tool  (
         <a class="graphic graphic_table graphicRef122197" href="/z/d/graphic/122197.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Grading'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Multidisciplinary care
         </strong>
         – A multidisciplinary team approach is recommended to evaluate clinical and neurologic status, which can rapidly change, to address the differential diagnosis in the context of changing neurologic function, and to decide whether specific treatments such as glucocorticoids or antiseizure medications should be given.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3080617926">
         <span class="h2">
          Clinical care setting
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical care setting should be reviewed on a daily basis to determine whether a patient can be managed on a regular medical floor or needs to be more closely monitored, such as in the setting of an intensive care unit (ICU).
        </p>
        <p>
         ICU care is generally advised in patients with progressive mental status changes and impaired responsiveness potentially related to worsening cerebral edema and/or status epilepticus, and in patients with higher-grade (grade 3 or 4) ICANS, so that close monitoring of neurologic, cardiovascular, and respiratory function can be provided.
        </p>
        <p class="headingAnchor" id="H3036371942">
         <span class="h2">
          Glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucocorticoids are an important component in the supportive management of patients with ICANS. The optimal timing, dose, and duration are not established, however, and treatment decisions are often influenced not only by ICANS but also concomitant cytokine release syndrome (CRS).
        </p>
        <p class="headingAnchor" id="H2252459146">
         <span class="h3">
          When to start
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based on the potential for rapid decline, we begin glucocorticoids in all patients with moderate to severe (grade ≥2) ICANS  (
         <a class="graphic graphic_table graphicRef122197" href="/z/d/graphic/122197.html" rel="external">
          table 2
         </a>
         ). Many of these patients will already be receiving such therapy due to concomitant CRS; for those who are not, or who have been tapered to lower doses, high-dose therapy is recommended.
        </p>
        <p>
         In the event that patients receive
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         for early and rapid onset of CRS (within 72 hours of infusion), one to two doses of glucocorticoids (eg,
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         5 to 10 mg) may be considered with tocilizumab [
         <a href="#rid68">
          68-70
         </a>
         ].
        </p>
        <p>
         Short-term high-dose glucocorticoids are generally well tolerated, although they can worsen agitation and delirium in some patients, which can confound the assessment of ICANS. There are also concerns that high-dose steroids may dampen the efficacy of immune effector cell (IEC) therapy. However, in the absence of a clear alternative, the risks of worsening ICANS demand treatment, particularly for severely affected patients.
        </p>
        <p>
         Observational evidence suggests that a brief course of steroids (eg, seven days or fewer) may shorten the course of ICANS without negatively affecting long-term cancer outcomes [
         <a href="#rid7">
          7
         </a>
         ]. However, definitive data are not available and additional prospective follow-up studies are needed.
        </p>
        <p class="headingAnchor" id="H1233188173">
         <span class="h3">
          Dose and duration
         </span>
         <span class="headingEndMark">
          —
         </span>
         While the specific dose and optimal daily dosing regimen is not established, most CRS and ICANS protocols suggest the use of
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         at a starting dose of 10 mg every 6 to 12 hours with a plan to taper over the following two to five days [
         <a href="#rid71">
          71
         </a>
         ]. In our experience, most patients will show rapid clinical improvement within hours to days of glucocorticoid initiation. Patients who do not show improvement over hours to days should be examined for alternative etiologies.
        </p>
        <p>
         In the absence of clear life-threatening seizures or cerebral edema, we favor beginning a taper after two to five days of high-dose steroids, since prolonged steroid use has been associated with inferior outcomes and steroid-related complications, including delirium, infections, and adrenal insufficiency. A typical taper consists of a 25 to 50 percent reduction in the total daily dose of steroid every 24 to 48 hours.
        </p>
        <p>
         Once patients appear to have returned to their previous neurologic baseline, steroids should be tapered completely off in an effort to avoid the potentially negative impact on the anticancer effect of CAR-T cell therapy. In one study, steroid use for less than 10 days appeared not to influence overall response to CAR-T cell therapy, although longer courses may be associated with worse clinical outcomes [
         <a href="#rid7">
          7,72
         </a>
         ].
        </p>
        <p>
         Depending on dose and duration of glucocorticoids, infectious prophylaxis may be indicated given an elevated risk of fungal, bacterial, and viral infections.
        </p>
        <p class="headingAnchor" id="H312836538">
         <span class="h2">
          Refractory edema
         </span>
         <span class="headingEndMark">
          —
         </span>
         Refractory cerebral edema with acutely increasing intracranial pressure (ICP) is a neurologic emergency. In the rare cases in which edema progresses rapidly despite steroids, patients require aggressive osmotic therapies such as
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         and hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         in an attempt to lower ICP.
        </p>
        <p>
         Patients receiving CAR-T therapies primarily for central nervous system (CNS) tumors may be at higher risk for cerebral edema and brain herniation syndromes in the context of tumor inflammation-associated neurotoxicity. Unique management considerations may apply to these patients, including monitoring in the ICU setting [
         <a href="#rid73">
          73
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1659.html" rel="external">
          "Evaluation and management of elevated intracranial pressure in adults", section on 'General management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2096435421">
         <span class="h2">
          Seizure prophylaxis and management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with ICANS are at increased risk for seizures. It can be difficult or impossible at the bedside to distinguish fluctuating encephalopathy from seizures, however, and EEG may take time to obtain.
        </p>
        <p>
         From a practical standpoint, we therefore suggest antiseizure medication therapy in most patients with suspected ICANS at the time of the initial presentation with neurologic symptoms. Prophylactic therapy is also reasonable to consider in patients deemed at high risk for seizures, such as those with prior seizure history, concerning EEG findings, or neoplastic brain lesions [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          Levetiracetam
         </a>
         is the preferred antiseizure medication in this patient population due to limited drug-drug interactions and less concern for added cardio- and hepatic toxicity [
         <a href="#rid47">
          47
         </a>
         ]. The usual starting dose is 500 mg twice daily.
        </p>
        <p>
         For patients with clinical or electrographic seizures, dose adjustments and other antiseizure medications (eg,
         <a class="drug drug_general" data-topicid="10268" href="/z/d/drug information/10268.html" rel="external">
          lacosamide
         </a>
         , benzodiazepines,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproic acid
         </a>
         ) may be needed [
         <a href="#rid53">
          53
         </a>
         ]. Interpretation of EEG patterns can be difficult and often requires continuous monitoring with clinical correlation. Patients with frequent seizures or concern for possible nonconvulsive status epilepticus should be managed in an ICU setting.
        </p>
        <p>
         The duration of antiseizure prophylaxis after recovery from ICANS has not been established, but the risk of recurrent seizures after the ICANS has resolved appears to be very low [
         <a href="#rid52">
          52
         </a>
         ]. In the authors' experience, most patients can be tapered off treatment safely within several weeks after CAR-T cell therapy.
        </p>
        <p class="headingAnchor" id="H2996895276">
         <span class="h2">
          Role of other therapies
         </span>
        </p>
        <p class="headingAnchor" id="H2993206909">
         <span class="h3">
          Tocilizumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with moderate to severe CRS with or without ICANS, the anti-interleukin (IL) 6 receptor
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         is typically given in combination with glucocorticoids [
         <a href="#rid47">
          47
         </a>
         ]. Earlier intervention with tocilizumab in a patient with both CRS and ICANS may possibly decrease the severity of ICANS, although this is controversial, and additional studies are needed. Use of tocilizumab in CRS is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/118012.html" rel="external">
          "Cytokine release syndrome (CRS)", section on 'CAR-T cell-associated CRS'
         </a>
         .)
        </p>
        <p>
         In patients with ICANS who do
         <strong>
          not
         </strong>
         have concurrent CRS, there is no role for
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         , which poorly crosses the blood-brain barrier (BBB). Prophylactic use of tocilizumab may potentially worsen ICANS by increasing IL-6 levels in cerebrospinal fluid (CSF) [
         <a href="#rid26">
          26,38,44,74
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2483425231">
         <span class="h3">
          Investigational therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of novel approaches to block inflammatory cytokines are under investigation, including IL-6 blockade with
         <a class="drug drug_general" data-topicid="95045" href="/z/d/drug information/95045.html" rel="external">
          siltuximab
         </a>
         [
         <a href="#rid74">
          74
         </a>
         ], IL-1 blockade with
         <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">
          anakinra
         </a>
         [
         <a href="#rid75">
          75,76
         </a>
         ], and granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralization with lenzilumab [
         <a href="#rid77">
          77
         </a>
         ]. However, their effects on CAR-T cell therapy and ICANS remain unknown, and such strategies are only appropriate in the context of a clinical trial.
        </p>
        <p class="headingAnchor" id="H2280140343">
         <span class="h1">
          LONG-TERM OUTCOMES
         </span>
         <span class="headingEndMark">
          —
         </span>
         With prompt recognition and appropriate supportive interventions, the acute symptoms of ICANS are reversible in nearly all patients. Long-term neurologic outcomes after successful chimeric antigen receptor T (CAR-T) cell therapy are not yet well studied, but the available data are reassuring [
         <a href="#rid78">
          78-80
         </a>
         ].
        </p>
        <p>
         In a single-center study of 56 consecutive patients treated with CAR-T cell therapy for relapsed diffuse large B cell lymphoma, baseline and follow-up neurologic examinations were available for 27 patients who were alive without tumor progression at six months or longer after treatment [
         <a href="#rid78">
          78
         </a>
         ]. Cognitive assessments were stable compared with the pretreatment baseline at a median of 7.6 months after treatment, including among 12 patients who developed acute neurotoxicity (all nonsevere). Self-assessment questionnaires highlighted clinically meaningful anxiety, depression, or cognitive difficulties at baseline in 63 percent of patients, improving to 44 percent at follow-up.
        </p>
        <p>
         Another study focused on the trajectory of perceived cognitive function in the first year after successful CAR-T cell therapy in 118 patients with lymphoma [
         <a href="#rid79">
          79
         </a>
         ]. Beyond three months posttreatment, questionnaires revealed mild changes in patient-reported global cognition, memory, language, executive function, and attention. Risk factors for such changes included more severe ICANS as well as baseline fatigue, anxiety, and depression.
        </p>
        <p>
         Other studies have shown a similar profile of neuropsychiatric symptoms in survivors of CAR-T cell therapy, highlighting the importance of multidisciplinary follow-up and supportive care [
         <a href="#rid81">
          81,82
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2490974509">
         <span class="h1">
          OTHER NEUROLOGIC TOXICITIES
         </span>
        </p>
        <p class="headingAnchor" id="H3283745324">
         <span class="h2">
          Delayed parkinsonism
         </span>
         <span class="headingEndMark">
          —
         </span>
         A delayed-onset movement disorder has been reported in several patients following administration of B cell maturation antigen (BCMA)-targeted chimeric antigen receptor T (CAR-T) cell therapy (
         <a class="drug drug_general" data-topicid="131213" href="/z/d/drug information/131213.html" rel="external">
          idecabtagene vicleucel
         </a>
         ,
         <a class="drug drug_general" data-topicid="135088" href="/z/d/drug information/135088.html" rel="external">
          ciltacabtagene autoleucel
         </a>
         ) [
         <a href="#rid35">
          35,83,84
         </a>
         ]. Whether these findings are related to on-target effects of CAR-T cells on BCMA-expressing astrocytes and neurons in the basal ganglia is still controversial [
         <a href="#rid83">
          83,85
         </a>
         ].
        </p>
        <p>
         In one case report, a 57-year-old male with advanced multiple myeloma was treated with
         <a class="drug drug_general" data-topicid="135088" href="/z/d/drug information/135088.html" rel="external">
          ciltacabtagene autoleucel
         </a>
         in a phase II trial and, beginning at approximately 100 days posttreatment, developed progressive parkinsonism, including bradykinesia, postural instability, hypophonia, hypomimia, micrographia, and mild tremor, as well as impaired short-term memory. Brain MRI was unremarkable; fluorodeoxyglucose-positron emission tomography (FDG-PET) scan showed hypometabolism in the caudate nuclei bilaterally compared with a pretreatment baseline. Serum studies showed persistent high levels of circulating CAR-T cells in the peripheral blood from days 11 through 157 postinfusion. There was no clinical response to levodopa, nor to immunosuppressive therapy with glucocorticoids and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         . The patient succumbed to febrile neutropenia, acute respiratory distress syndrome, and multiorgan failure on day 162. Postmortem studies showed focal gliosis in the caudate nuclei as well as BCMA expression in a subset of neurons and astrocytes in the caudate and frontal cortex.
        </p>
        <p>
         A second case report described a 74-year-old male with advanced multiple myeloma treated with
         <a class="drug drug_general" data-topicid="135088" href="/z/d/drug information/135088.html" rel="external">
          ciltacabtagene autoleucel
         </a>
         [
         <a href="#rid85">
          85
         </a>
         ]. Neurocognitive impairment and difficulty walking developed 20 days after infusion, and examination revealed parkinsonism. Brain MRI was unremarkable. The patient demonstrated modest improvement following 10 days of
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         and
         <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">
          anakinra
         </a>
         ; however, he continued to have robust lymphocyte expansion (11,150 cells/microL in peripheral blood, which were later demonstrated to be 99 percent CAR-T cells). He was treated with 2 g/m
         <sup>
          2
         </sup>
         intravenous (IV)
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , and neurologic symptoms began to improve within 24 hours and continued to improve during a three-month
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         taper. Interestingly, despite high-dose cyclophosphamide, polyclonal CAR-T cells were still detectable in peripheral blood 90 days from infusion and, when isolated, were still functional based on in vitro killing assays.
        </p>
        <p>
         To date, the syndrome has only been described after BCMA-targeted CAR-T cell therapy. Two other patients with grade 3 parkinsonism were reported in phase II trials of
         <a class="drug drug_general" data-topicid="135088" href="/z/d/drug information/135088.html" rel="external">
          ciltacabtagene autoleucel
         </a>
         [
         <a href="#rid83">
          83
         </a>
         ], and grade 3 parkinsonism is included as an adverse event in the
         <a class="drug drug_general" data-topicid="131213" href="/z/d/drug information/131213.html" rel="external">
          idecabtagene vicleucel
         </a>
         package insert [
         <a href="#rid84">
          84
         </a>
         ]. Data are still evolving. Supportive care is indicated, although best management practices are not established.
        </p>
        <p class="headingAnchor" id="H1882514250">
         <span class="h2">
          Myelopathy and polyneuropathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are accumulating reports of neurologic toxicities falling outside of the ICANS spectrum as currently defined, including cases of transverse myelitis, Guillain-Barré syndrome (GBS), acute disseminated encephalomyelopathy (ADEM), and cranial neuropathies [
         <a href="#rid86">
          86-91
         </a>
         ]. Most reports have described a response to high-dose glucocorticoids with or without intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG), but severe and fatal cases have occurred.
        </p>
        <p>
         These toxicities are believed to be immune-mediated, but the mechanism is not yet well understood. Cases have been reported during, after, and without associated cytokine release syndrome (CRS) and/or ICANS. In at least one case of GBS, nerve conduction studies showed an axonal pattern of nerve damage, and muscle-nerve biopsies contained T cell-rich infiltrates with CAR transgene detected, implying CAR-T cell-mediated inflammation [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
         A variety of specific products have been implicated, including
         <a class="drug drug_general" data-topicid="115350" href="/z/d/drug information/115350.html" rel="external">
          axicabtagene ciloleucel
         </a>
         ,
         <a class="drug drug_general" data-topicid="135088" href="/z/d/drug information/135088.html" rel="external">
          ciltacabtagene autoleucel
         </a>
         ,
         <a class="drug drug_general" data-topicid="131213" href="/z/d/drug information/131213.html" rel="external">
          idecabtagene vicleucel
         </a>
         , and
         <a class="drug drug_general" data-topicid="114674" href="/z/d/drug information/114674.html" rel="external">
          tisagenlecleucel
         </a>
         . While these complications are considered very rare, warnings regarding risk of immune-mediated myelitis and GBS have been added to the package insert of ciltacabtagene autoleucel [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3759303252">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Incidence
         </strong>
         – Immune effector cell-associated neurotoxicity syndrome (ICANS)
         <em>
         </em>
         is a neuropsychiatric syndrome that occurs in up to 70 percent of patients following administration of certain types of immunotherapy  (
         <a class="graphic graphic_table graphicRef130108" href="/z/d/graphic/130108.html" rel="external">
          table 1
         </a>
         ), especially chimeric antigen receptor T (CAR-T) cell therapy and certain T cell engaging monoclonal antibodies. (See
         <a class="local">
          'Incidence and risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathophysiology
         </strong>
         – The pathophysiology of ICANS is not well understood. It is thought that systemic inflammation and high levels of circulating cytokines lead to endothelial cell activation, blood-brain barrier (BBB) disruption, and an inflammatory central nervous system (CNS) cascade. (See
         <a class="local">
          'Pathophysiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – ICANS usually occurs in the context of cytokine release syndrome (CRS), beginning 3 to 10 days after CAR-T cell administration and within 2 to 4 days of CRS onset. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Signs and symptoms
         </strong>
         – The most common symptoms are alterations in level of consciousness, confusion, behavioral changes, and speech and language abnormalities. Patients are at increased risk for seizures, diffuse cerebral edema, and elevated intracranial pressure (ICP). (See
         <a class="local">
          'Clinical presentation'
         </a>
         above and
         <a class="local">
          'Electroencephalography'
         </a>
         above and
         <a class="local">
          'Neuroimaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Severity and grading
         </strong>
         – ICANS is graded according to the most severe symptom in five domains  (
         <a class="graphic graphic_table graphicRef122197" href="/z/d/graphic/122197.html" rel="external">
          table 2
         </a>
         ): encephalopathy (immune effector cell-associated encephalopathy [ICE] score), level of consciousness, seizure, motor findings, and elevated ICP/cerebral edema. (See
         <a class="local">
          'Grading'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – ICANS should be suspected in any patient who develops new neurologic symptoms in the setting of recent immune effector cell (IEC) therapy. It is a diagnosis of exclusion after other potential causes of mental status changes or altered neurologic function have been ruled out. (See
         <a class="local">
          'Evaluation and diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Neuroimaging and EEG are required in most patients to evaluate for alternative etiologies and diagnose seizures. Cerebrospinal fluid (CSF) examination is indicated when there is suspicion for CNS infection. (See
         <a class="local">
          'Additional testing'
         </a>
         above and
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Management of ICANS requires vigilance and close supportive care, and early recognition is paramount. Treatment is supportive and consists primarily of glucocorticoids and antiseizure medications. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Monitoring
         </strong>
         – Intensive care unit (ICU) care is generally advised in patients with progressive mental status changes and impaired responsiveness potentially related to worsening cerebral edema and/or status epilepticus, and in patients with higher-grade (grade 3 or 4) ICANS  (
         <a class="graphic graphic_table graphicRef122197" href="/z/d/graphic/122197.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Clinical monitoring'
         </a>
         above and
         <a class="local">
          'Clinical care setting'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Glucocorticoids
         </strong>
         – Based on the potential for rapid decline, we treat all patients with moderate to severe (grade ≥2) ICANS  (
         <a class="graphic graphic_table graphicRef122197" href="/z/d/graphic/122197.html" rel="external">
          table 2
         </a>
         ) with glucocorticoids. Many of these patients will already be receiving such therapy due to concomitant CRS; for those who are not or who have been tapered to lower doses, high-dose therapy should be started. (See
         <a class="local">
          'Glucocorticoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Seizure prophylaxis
         </strong>
         – Patients are at risk for seizures, but clinical diagnosis is complicated and often confounded by encephalopathy. We therefore suggest starting most patients on an antiseizure medication such as
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         at the time of first neurologic symptoms. (See
         <a class="local">
          'Seizure prophylaxis and management'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019; 25:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frigault MJ, Maus MV. State of the art in CAR T cell therapy for CD19+ B cell malignancies. J Clin Invest 2020; 130:1586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang ML, Munoz J, Goy A, et al. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients (Pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL): Results of the phase 2 ZUMA-2 study. Blood 2019; 134:754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schuster SJ, JULIET Investigators. Tisagenlecleucel in diffuse large B-cell lymphoma. Reply. N Engl J Med 2019; 380:1586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 2017; 377:2531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holtzman NG, Xie H, Bentzen S, et al. Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. Neuro Oncol 2021; 23:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karschnia P, Jordan JT, Forst DA, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood 2019; 133:2212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019; 380:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 2020; 396:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med 2021; 384:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riedell PA, Walling C, Nastoupil LJ, et al. A multicenter retrospective analysis of clinical outcomes, toxicities, and patterns of use in institutions utilizing commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B-cell lymphomas. Blood 2019; 134:1599.
          </a>
         </li>
         <li class="breakAll">
          Pasquini MC, Locke FL, Herrera AF, et al. Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (Axi-Cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US). American Society of Hematology Annual Meeting &amp; Exposition, Washington, DC, December 9, 2019.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaglowski S, Hu ZH, Zhang Y, et al. Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for adults with diffuse large B-cell lymphoma (DLBCL): Real world experience from the Center for International Blood &amp; Marrow Transplant Research (CIBMTR) cellular therapy (CT) registry. Blood 2019; 134:766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawalekar OU, O'Connor RS, Fraietta JA, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 2016; 44:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ying Z, He T, Wang X, et al. Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted CAR-T cells for B cell non-Hodgkin's lymphoma. Mol Ther Oncolytics 2019; 15:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyiadzis MM, Dhodapkar MV, Brentjens RJ, et al. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: Clinical perspective and significance. J Immunother Cancer 2018; 6:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 2018; 131:1522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 2017; 376:836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein AS, Schiller G, Benjamin R, et al. Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: Management and mitigating factors. Ann Hematol 2019; 98:159.
          </a>
         </li>
         <li class="breakAll">
          teclistamab-cqyv. United States prescribing information. Revised October 2022. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761291s000lbl.pdf (Accessed on October 27, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 2023; 29:2259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol 2022; 23:1055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 2022; 387:2220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol 2023; 41:2238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med 2022; 387:2232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gust J, Hay KA, Hanafi LA, et al. Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov 2017; 7:1404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santomasso BD, Park JH, Salloum D, et al. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. Cancer Discov 2018; 8:958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin DB, Danish HH, Ali AB, et al. Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain 2019; 142:1334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 2016; 127:3321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin DB, Al Jarrah A, Li K, et al. Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy. JAMA Neurol 2020; 77:1536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frigault MJ, Dietrich J, Martinez-Lage M, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood 2019; 134:860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frigault MJ, Dietrich J, Gallagher K, et al. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood 2022; 139:2306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6:224ra25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med 2019; 380:1726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karschnia P, Miller KC, Yee AJ, et al. Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells. Blood 2023; 142:1243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 2017; 130:2295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobson CA, Rosenthal AC, Arnason J, et al. A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell-associated neurotoxicity syndrome. Blood Adv 2023; 7:6790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Locke FL, Neelapu SS, Bartlett NL, et al. Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL). Blood 2017; 130:1547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobson CA, Hunter BD, Redd R, et al. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. J Clin Oncol 2020; 38:3095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chou CK, Turtle CJ. Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy. Bone Marrow Transplant 2019; 54:780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rice J, Nagle S, Randall J, Hinson HE. Chimeric antigen receptor T cell-related neurotoxicity: Mechanisms, clinical presentation, and approach to treatment. Curr Treat Options Neurol 2019; 21:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taraseviciute A, Tkachev V, Ponce R, et al. Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates. Cancer Discov 2018; 8:750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 2018; 24:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gust J, Finney OC, Li D, et al. Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Ann Neurol 2019; 86:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torre M, Solomon IH, Sutherland CL, et al. Neuropathology of a case with fatal CAR T-cell-associated cerebral edema. J Neuropathol Exp Neurol 2018; 77:877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karschnia P, Arrillaga-Romany IC, Eichler A, et al. Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells. Neuro Oncol 2023; 25:2239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 2018; 15:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzalez Castro LN, Dietrich J, Forst DA. Stuttering as the first sign of CAR-T-cell-related encephalopathy syndrome (CRES). J Cancer Res Clin Oncol 2019; 145:1917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sokolov E, Karschnia P, Benjamin R, et al. Language dysfunction-associated EEG findings in patients with CAR-T related neurotoxicity. BMJ Neurol Open 2020; 2:e000054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guha-Thakurta N, Wierda WG. Cerebral edema secondary to chimeric antigen receptor T-cell immunotherapy. Neurology 2018; 91:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strati P, Nastoupil LJ, Westin J, et al. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 2020; 4:3943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beuchat I, Danish HH, Rubin DB, et al. EEG findings in CAR T-cell-associated neurotoxicity: Clinical and radiological correlations. Neuro Oncol 2022; 24:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herlopian A, Dietrich J, Abramson JS, et al. EEG findings in CAR T-cell therapy-related encephalopathy. Neurology 2018; 91:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gust J, Ishak GE. Chimeric antigen receptor T-cell neurotoxicity neuroimaging: More than meets the eye. AJNR Am J Neuroradiol 2019; 40:E50.
          </a>
         </li>
         <li class="breakAll">
          Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. National Cancer Institute. Available at: https://evs.nci.nih.gov/ftp1/CTCAE/About.html (Accessed on September 24, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Traube C, Silver G, Kearney J, et al. Cornell Assessment of Pediatric Delirium: a valid, rapid, observational tool for screening delirium in the PICU*. Crit Care Med 2014; 42:656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maus MV, Nikiforow S. The why, what, and how of the new FACT standards for immune effector cells. J Immunother Cancer 2017; 5:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gust J, Annesley CE, Gardner RA, Bozarth X. EEG Correlates of Delirium in Children and Young Adults With CD19-Directed CAR T Cell Treatment-Related Neurotoxicity. J Clin Neurophysiol 2021; 38:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowe KL, Mackall CL, Norry E, et al. Fludarabine and neurotoxicity in engineered T-cell therapy. Gene Ther 2018; 25:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zabernigg A, Maier H, Thaler J, Gattringer C. Late-onset fatal neurological toxicity of fludarabine. Lancet 1994; 344:1780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson RC, Patel V, Sheikh-Bahaei N, et al. Posterior reversible encephalopathy syndrome (PRES): Pathophysiology and neuro-imaging. Front Neurol 2020; 11:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheikh MA, Toledano M, Ahmed S, et al. Noninfectious neurologic complications of hematopoietic cell transplantation: A systematic review. Hematol Oncol Stem Cell Ther 2021; 14:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mosna K, Ladicka M, Drgona L, et al. Ibrutinib treatment of mantle cell lymphoma complicated by progressive multifocal leukoencephalopathy . Int J Clin Pharmacol Ther 2020; 58:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sdrimas K, Diaz-Paez M, Camargo JF, Lekakis LJ. Progressive multifocal leukoencephalopathy after CAR T therapy. Int J Hematol 2020; 112:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neil EC, DeAngelis LM. Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review. Blood Adv 2017; 1:2041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santomasso BD, Nastoupil LJ, Adkins S, et al. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. J Clin Oncol 2021; 39:3978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maus MV, Alexander S, Bishop MR, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer 2020; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Topp MS, van Meerten T, Houot R, et al. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol 2021; 195:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oluwole OO, Forcade E, Munoz J, et al. Prophylactic corticosteroid use with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL): One-year follow-up of ZUMA-1 cohort 6 (C6). Blood 2021; 138 (Supplement 1):2832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oluwole OO, Bouabdallah K, Munoz J, et al. Prophylactic steroid use with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory large B cell lymphoma (R/R LBCL). Transplant Cell Ther 2021; 27 (Supplement):S68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol 2019; 37 Suppl 1:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strati P, Furqan F, Westin J, et al. Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel). J Clin Oncol 2020; 38:8011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahdi J, Dietrich J, Straathof K, et al. Tumor inflammation-associated neurotoxicity. Nat Med 2023; 29:803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen F, Teachey DT, Pequignot E, et al. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. J Immunol Methods 2016; 434:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giavridis T, van der Stegen SJC, Eyquem J, et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med 2018; 24:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strati P, Jallouk A, Deng Q, et al. A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma. Blood Adv 2023; 7:6785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sterner RM, Sakemura R, Cox MJ, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood 2019; 133:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maillet D, Belin C, Moroni C, et al. Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study. Neuro Oncol 2021; 23:1569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barata A, Hoogland AI, Kommalapati A, et al. Change in Patients' Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma. Transplant Cell Ther 2022; 28:401.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ursu R, Maillet D, Belin C, et al. Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. Neurology 2022; 99:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cordeiro A, Bezerra ED, Hirayama AV, et al. Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. Biol Blood Marrow Transplant 2020; 26:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruark J, Mullane E, Cleary N, et al. Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy. Biol Blood Marrow Transplant 2020; 26:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Oekelen O, Aleman A, Upadhyaya B, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med 2021; 27:2099.
          </a>
         </li>
         <li class="breakAll">
          ABECMA idecaptagene vicleucel suspension prescribing information https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b90c1fe7-f5cc-464e-958a-af36e9c26d7c&amp;type=display (Accessed on January 03, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graham CE, Lee WH, Wiggin HR, et al. Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood 2023; 142:1248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gritsch D, Valencia-Sanchez C. Drug-related immune-mediated myelopathies. Front Neurol 2022; 13:1003270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beauvais D, Cozzani A, Blaise AS, et al. A potential role of preexisting inflammation in the development of acute myelopathy following CAR T-cell therapy for diffuse large B-cell lymphoma. Curr Res Transl Med 2022; 70:103331.
          </a>
         </li>
         <li class="breakAll">
          CARVYKTI (ciltacabtagene autoleucel) https://www.fda.gov/media/156560/download.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nair R, Drillet G, Lhomme F, et al. Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy. Haematologica 2021; 106:1504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koch C, Fleischer J, Popov T, et al. Diabetes insipidus and Guillain-Barré-like syndrome following CAR-T cell therapy: a case report. J Immunother Cancer 2023; 11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheikh S, Mokhtari S, Silverman JA, et al. Transverse myelitis after anti-CD19 directed CAR T cell therapy for relapsed large B cell lymphoma. EJHaem 2022; 3:223.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 129618 Version 15.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30592986" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32235098" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : State of the art in CAR T cell therapy for CD19+ B cell malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients (Pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL): Results of the phase 2 ZUMA-2 study
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30995384" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Tisagenlecleucel in Diffuse Large B-Cell Lymphoma. Reply.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29226797" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32750704" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30808634" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30501490" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32888407" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33626253" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : A multicenter retrospective analysis of clinical outcomes, toxicities, and patterns of use in institutions utilizing commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B-cell lymphomas
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : A multicenter retrospective analysis of clinical outcomes, toxicities, and patterns of use in institutions utilizing commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B-cell lymphomas
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for adults with diffuse large B-cell lymphoma (DLBCL): Real world experience from the Center for International Blood&amp;Marrow Transplant Research (CIBMTR) cellular therapy (CT) registry
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31650026" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30514386" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29358182" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28249141" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30238148" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30238148" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37582952" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35803286" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36507690" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36548927" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36507686" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29025771" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29880584" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30891590" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Neurological toxicities associated with chimeric antigen receptor T-cell therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27207799" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Toxicities of chimeric antigen receptor T cells: recognition and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32777012" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31320380" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35167655" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24553386" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31042825" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37471607" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28924019" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37399456" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell-associated neurotoxicity syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32667831" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31431714" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31327064" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29563103" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29808007" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31074527" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30060228" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37402650" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28925994" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30539279" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Stuttering as the first sign of CAR-T-cell-related encephalopathy syndrome (CRES).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33681787" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Language dysfunction-associated EEG findings in patients with CAR-T related neurotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30373920" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Cerebral edema secondary to chimeric antigen receptor T-cell immunotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32822484" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34265061" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : EEG findings in CAR T-cell-associated neurotoxicity: Clinical and radiological correlations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29959264" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : EEG findings in CAR T-cell therapy-related encephalopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31488503" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Chimeric Antigen Receptor T-Cell Neurotoxicity Neuroimaging: More Than Meets the Eye.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31488503" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Chimeric Antigen Receptor T-Cell Neurotoxicity Neuroimaging: More Than Meets the Eye.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24145848" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Cornell Assessment of Pediatric Delirium: a valid, rapid, observational tool for screening delirium in the PICU*.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28428885" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The Why, what, and How of the New FACT standards for immune effector cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31851018" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : EEG Correlates of Delirium in Children and Young Adults With CD19-Directed CAR T Cell Treatment-Related Neurotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29789639" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Fludarabine and neurotoxicity in engineered T-cell therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7997036" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Late-onset fatal neurological toxicity of fludarabine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32612567" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Posterior Reversible Encephalopathy Syndrome (PRES): Pathophysiology and Neuro-Imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32516577" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Noninfectious neurologic complications of hematopoietic cell transplantation: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32213285" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Ibrutinib treatment of mantle cell lymphoma complicated by progressive multifocal leukoencephalopathy .
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32125605" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Progressive multifocal leukoencephalopathy after CAR T therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29296850" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34724386" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33335028" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34590303" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Prophylactic corticosteroid use with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL): One-year follow-up of ZUMA-1 cohort 6 (C6)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Prophylactic steroid use with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory large B cell lymphoma (R/R LBCL)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31187535" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Managing the toxicities of CAR T-cell therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37024595" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Tumor inflammation-associated neurotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27049586" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29808005" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37389847" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30463995" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33822183" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35580732" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Change in Patients' Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35851255" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31419568" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31605820" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34893771" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34893771" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37467494" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36247761" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Drug-related immune-mediated myelopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34999480" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : A potential role of preexisting inflammation in the development of acute myelopathy following CAR T-cell therapy for diffuse large B-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34999480" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : A potential role of preexisting inflammation in the development of acute myelopathy following CAR T-cell therapy for diffuse large B-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32732365" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36690387" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Diabetes insipidus and Guillain-Barré-like syndrome following CAR-T cell therapy: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35846190" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Transverse myelitis after anti-CD19 directed CAR T cell therapy for relapsed large B cell lymphoma.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
